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Absence of carriage of glycopeptide-
resistant enterococci by at-risk
hospitalised patients in Malta
In a recent article in Clinical Microbiology and
Infection, Cordeiro et al. [1] described the inter-
hospital dissemination of glycopeptide-resistant
enterococci (GRE) in Brazil. These organisms are
isolated mainly from patients in intensive care,
transplant and oncology units, and this has been
attributed particularly to the use of combination
antimicrobial therapy involving vancomycin and
anti-anaerobe agents, coupled with prolonged
hospitalisation [2,3]. GRE have a major impact
on the management of patients and wards [4], and
gastrointestinal colonisation with GRE is difficult
to eradicate once it is established [5,6].
There have been no previous reports of GRE in
Malta, which is an island in the Mediterranean
with a population of 450 000. This contrasts with
other countries in the region, where the preval-
ence of GRE in blood culture isolates has been
reported to reach 2% [7]. Glycopeptide use
(predominantly teicoplanin) in Malta is common
because of the high prevalence of methicillin-
resistant Staphylococcus aureus infections in
St Luke’s Hospital, which is the only tertiary care
hospital (with 900 beds, including a 13-bed
intensive care unit) on the island. In order to
establish whether the at-risk population in this
hospital harboured GRE, a 4-month screening
programme, concentrating on the intensive care
unit, was performed in June to September 2002.
In total, 310 rectal swabs were taken from 300
patients and inoculated into VRE broth (Oxoid,
Basingstoke, UK) supplemented with meropenem
(Oxoid) 1 mg ⁄mL and colistin sulphate (Pharmax,
Bexley, UK) 7.5 mg ⁄L (to suppress the growth of
meropenem-resistant Pseudomonas aeruginosa).
Control experiments demonstrated that this broth
supported the growth of the standard strains
Enterococcus faecalis NCTC 12201 (vanA+),
E. faecalis ATCC 33186 (glycopeptide-susceptible)
and Enterococcus faecium ATCC 51559 (vanA+).
Following incubation at 37C for 16 h, the broths
were streaked on to VRE agar (Oxoid) supple-
mented with meropenem 0.5 mg ⁄L and vanco-
mycin (Oxoid) 6 mg ⁄L. Following incubation at
37C for 24–48 h, putative enterococci were iden-
tified to the species level with the API STREP
system (bioMe´rieux, Marcy l’Etoile, France), and
susceptibilities to vancomycin and teicoplanin
were determined with Etests (AB Biodisk, Solna,
Sweden).
Only one isolate of GRE was recovered during
the 4-month screening period. This isolate was
identified as E. faecium (vancomycin MIC
> 32 mg ⁄L; teicoplanin MIC 32 mg ⁄L) and was
shown by PCR to carry the vanA gene. The
patient was a poultry farm worker and was
screened on the first day following admission to
the intensive care unit. The patient was not
receiving any antimicrobial therapy and had no
previous history of prolonged hospitalisation.
Interestingly, the presence of GRE in Europe has
been linked to the use of avoparcin in animal
husbandry [8]. Avoparcin was used in poultry
farms in Malta until August 1999, when its
importation was banned, but residual stocks may
well remain at some farms.
GRE are now found worldwide, but these
results confirmed that the prevalence of GRE
within St Luke’s Hospital remains negligible.
Since St Luke’s is the only tertiary hospital on
the island, it seems that the prevalence of GRE in
Malta is considerably lower than that reported in
many other European countries.
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Zygomycosis in neutropenic patients with
past Aspergillus infection: a role for
posaconazole?
In the March 2004 supplement of Clinical Micro-
biology and Infection, Donnelly and De Pauw [1]
published a review on voriconazole, with empha-
sis on its use for treating cases of candidosis,
invasive aspergillosis, and some more uncommon
mycoses caused by Scedosporium spp. and
Fusarium spp. Voriconazole has little activity
against Sporothrix schenckii and zygomycetes such
as Mucor spp., Rhizopus spp. and Absidia spp. [1].
Thus, selective pressure from prolonged courses
of voriconazole, or increased survival among
profoundly immunosuppressed patients, may
explain the higher incidence of zygomycosis in
patients who remain at obvious risk for invasive
fungal infections [2].
Marty et al. [2] have described breakthrough
zygomycoses in recipients of allogenic haemato-
poietic stem-cell transplants since the introduction
of voriconazole, and we would like to report a
similar case of a man aged 65 years, diagnosed
with acute myeloid leukaemia, who received vor-
iconazole for proven neutropenia-induced inva-
sive pulmonary aspergillosis (i.e., respiratory
samples positive ondirect examination and culture
for Aspergillus fumigatus; serum galactomannan
positive on several occasions; compatible thorax
lesions visualised by computerised tomography
scan). While receiving voriconazole, the patient
developed a massive maxillary and ethmoidal
sinusitis, with proptosis of the right eye showing
hyphal elements on direct examination of tissue
samples. Culture remained sterile. Therapy was
altered to amphotericin B, but persistence of the
lesions prompted a Caldwell–Luc debridement.
Tissue samples nowrevealed fungal elements, seen
typically in cases of zygomycosis, comprising
thick-walled, aseptate right-angle branching fila-
ments (Fig. 1) [3]. Culture yielded no growth. The
patient’s therapy was changed to oral posaconaz-
ole 800 mg daily [4,5]. The patient recovered and
continues to receive posaconazole 400 mg daily
without major side effects.
We conclude that posaconazole is a potentially
useful therapy for patients developing break-
through zygomycosis after long-term use of voric-
onazole.Agood responsehas alreadybeen reported
in a case of invasive aspergillosis treated with
posaconazole [6], but it is not yet clear whether this
drug is appropriate for the first-line treatment of
non-Candidamycoses in these patients.
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Fig. 1. Thick-walled, aseptate right-angle branching
filaments, seen typically in cases of zygomycosis
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